A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteers, Alzheimer Disease

In brief

This study involves single and multiple doses of LY3202626 and will evaluate the effects of LY3202626 on the body. There will be 4 parts to this study. In Parts A and B, single increasing doses of LY3202626 will be given in capsule form. Part A will also include itraconazole given orally as a solution. Part A will last approximately 8-12 weeks. Part B will last approximately 5-6 weeks. In Parts C and D, participants will be dosed multiple days with the study drug. Part C will last approximately 11-14 weeks. Part D will last approximately 11-14 weeks and participants must have Alzheimer's Disease. Participants may only enroll in one part.

Key facts

Study ID
NCT02323334
Run by
Eli Lilly and Company
People needed
94
Starts
2014-12-01
Expected to finish
2016-02-01
Last updated by the study team
2021-04-19

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.